Hero

News & Events

Mestag in the News
BioCentury Article: Mestag: Attacking Tumors from Within

Fierce Biotech: Merck & Co. signs $1.9B deal with Mestag to explore fibroblast therapies for inflammation

Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer

Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

December 9, 2024

Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel

November 13, 2024

Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

October 8, 2024

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

August 28, 2024

View All Press Releases

BioEquity Europe – Bruges, Belgium

Company Presentation

May 13, 2025 at 4:30pm

Conference Website

ASCO Annual Meeting – Chicago, IL

May 30 - June 3, 2025

Conference Website